The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Call to integrate supportive care and patient reported outcomes in early phase clinical trials: An exploration of adolescent and young adult (AYA) participation on phase I trials of novel anticancer agents.
 
Ishwaria Mohan Subbiah
No Relationships to Disclose
 
Chad Tang
No Relationships to Disclose
 
Arvind Rao
No Relationships to Disclose
 
Vivek Subbiah
Research Funding - Novartis, GSK, Nanocarrier, NorthWest Biotherapeutics, Roche/Genentech, BergPharma, Bayer, Incyte, FujiFilm, Pharmamar, D3, Pfizer Amgen, Abbvie, Multivir, Bluprint Medicines.
Travel, Accommodations, Expenses - Novartis, Pharmamar, Fujifilm
 
Razelle Kurzrock
Leadership - CureMatch
Stock and Other Ownership Interests - Actuate Therapeutics; CureMatch
Honoraria - AACR; AACR; AACR; Actuate Therapeutics; Casdin Capital; Casdin Capital; Casdin Capital; Casdin Capital; Cedars-Sinai; CME Education Resources; Defined Health; Frankel Group; Global Biomarkers Consortium; Health Advances; Janssen; Jubilant Biosys; Kaiser Permanente; Mayo Clinic Cancer Center; NCCN; Northwestern University; NXT Health Strategies; NXT Health Strategies; Pancreatic Cancer Action Network; Scripps Translational Science Institute; Scripps Translational Science Institute; Segal Cancer Center; Seminars in Oncology; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; Sylvester Cancer Center; Sylvester Cancer Center; The Dedham Group; UCSD Genomics Program Talk; Wiley; XBiotech; XBiotech; Yale Cancer Center
Consulting or Advisory Role - AACR; Actuate Therapeutics; CTRC-EAB San Antonio; Janssen; Jubilant Biosys; Merck; SAIC NCI CCCT IDSE; Sequenom; XBiotech
Research Funding - Centocor Ortho Biotech (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Exelixis (Inst); Foundation Medicine (Inst); Foundation Medicine (Inst); Genentech (Inst); Genentech Mypath (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Merck (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sequenom (Inst); XBiotech
Patents, Royalties, Other Intellectual Property - Patent; Patent; Patent; Patent
Travel, Accommodations, Expenses - AACR; AACR; ASCPT; Association of American Cancer Institutes; Caris Centers of Excellence; Caris Centers of Excellence; Cedars-Sinai; CureMatch; Defined Health; EMD Serono; EMD Serono & Quintiles; EMD Serono & Quintiles; FDA-OCRA; Gateway Research Advisory Committee; Gateway Research Advisory Committee; Genentech; Global Biomarkers Consortium; Global Source Ventures/Novena Therapeutics; Guardant Health; Guardant Health; ICRP; IST GmbH; Journal of Precision Medicine; Kaiser Permanente; Lynx Group; Mayo Clinic Cancer Center; MedImmune/JK Associates Medical Communications Group; Meyer; Meyer; Orbimed/Global Source Ventures; Pancreatic Cancer Action Network; Pancreatic Cancer Action Network; Sylvester Cancer Center; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Baxter; Bayer
Research Funding - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genentech; Lilly; Merck; Mirati Therapeutics; miRNA Therapeutics; Novartis; Pfizer
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
Other Relationship - Oncorena